ENALAPRIL MALEATE | A212408 | BIONPHARMA INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
AZURITY PHARMACEUTICALS, INC. v. NOVITIUM PHARMA, LLC 2 patentsANDA 212408enalapril maleate | D. Del. | 2023-02-14 | Terminated 2024-04-08 | — |
AZURITY PHARMACEUTICALS, INC. v. NOVITIUM PHARMA, LLC 2 patentsANDA 212408enalapril maleate | D.N.J. | 2022-10-03 | Terminated 2023-01-23 | — |
| D. Del. | 2021-10-15 | Terminated 2025-01-02 | — | |
Silvergate Pharmaceuticals, Inc. v. Bionpharma Inc. 3 patentsANDA 212408enalapril maleate | D. Del. | 2018-12-12 | Terminated 2021-05-17 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$0.9921
per ml
Lowest NADAC/Unit
$0.9921
per ml
Brand NDCs
0
Generic NDCs
1
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 69452023746ENALAPRIL 1 MG/ML ORAL SOLN | $0.9921 | ML | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.